Endothelial dysfunction precedes atherosclerosis in systemic sclerosis - Relevance for prevention of vascular complications

Rheumatology

Volumn 46, Issue 5, 2007, Pages 759-762

  Szucs G ^a   Timar O ^a   Szekanecz, Z ^a   Der H ^a   Kerekes, G ^a   Szamosi, S ^a   Shoenfeld, Y ^b   Szegedi, G ^c   Soltesz P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SHEBA MEDICAL CENTER   (Israel)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; DIAGNOSTIC AGENT; VASODILATOR AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY INTIMA; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; HUMAN; MALE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASODILATATION; AGE; ARTICLE; INTIMA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; TIME; TUNICA MEDIA; VASCULAR ENDOTHELIUM;

ADULT; AGE FACTORS; AGED; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY, COMMON; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROGLYCERIN; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA; VASODILATION; VASODILATOR AGENTS;

EID: 34347214839     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel426     Document Type: Review

References (25)

1. Veale DJ, Collidge TA, Belch J. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995;54:853-5.
2. Ho M, Veale DJ, Eastmond C, Nuki G, Belch J. Macrovascular disease in systemic sclerosis. Ann Rheum Dis 2000;59:39-43.
3. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112;3337-47.
4. Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nature Clin Pract Rheumatol 2006;2:1-8.
5. LeRoy CE. Systemic sclerosis: A vascular perspective. Rheum Dis Clin N Am 1996;22:675.
6. Matucci Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Furst D, Clements P, eds. Systemic sclerosis. Baltimore, MD; Lippincott Williams and Wilkins, 2003;241.
7. Matucci-Cerinic M, Valentini G, Sorano GG et al. Blood coagulation, fibrinolysis and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003;32:285-92.
8. Lekakis J, Mavrikakis M, Papamichael C et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998; 136:905-12.
9. Cheng KS, Tiwari A, Boutin A et al. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology 2003;42:1299-305.
10. Sulli A, Ghio M, Bezanyte GP et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology 2004;43:505-9.
11. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-65.
12. Marasini B, Casari S, Bestetti A et al. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J Rheumatol 2000;27:2621-3.
13. Herrick A, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19:1-4.
14. Szamosi S, Csiki Z, Szomják E, Szolnoli E et al. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis. J Rheumatol, in press.
15. Szücs G, Szomjäk E, Csiki Z et al. Correlation between the level of serum soluble endothel adhesion molecules, endothelium-associoated cytokines and homocysteine level in patents with systemic sclerosis, atherosclerosis obliterans and primary Raynaud syndrome. Ann Rheum Dis 2002;61(Suppl 1):403.
16. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
17. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
18. Kanters SDJM, Algra A, van Leeuwen MS, Bangs JD. Reproducibility of in vivo carotid intima-media thickness measurements. Stroke 1997;28:665-71.
19. Gordon PA, George J, Khamashta MA, Harats D, Hughes G, Shoenfeld Y. Atherosclerosis and autoimmunity. Lupus 2001;4:249-52.
20. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: Lessons from experimental models. Lupus 2000;3:223-27.
21. Neunteufi T, Katzenschlager R, Hassan A et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-8.
22. Schachinger V, Zeiher AM. Atherosclerosis-associated endothelial dysfunction. Z Kardiol 2000;89:70-4.
23. Zakopoulos NA, Kotsis VT, Gialafos EJ et al. Systemic sclerosis is not associated with clinical or ambulatory blood pressure. Clin Exp Rheumatol 2003;21:199-204.
24. Anderson GN, Mincheva-Nilsson L, Kazzam E et al. Assessment of vascular function in systemic sclerosis: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002;46:1324-32.
25. Kerekes G, Bodolay E, Sipka S et al. Endothelial dysfunction and early atherosclerosis in undifferentiated collagenosis. Hung Med J (Orv Hetil) 2005;146:791-5.